DOI: https://doi.org/10.26641/2307-0404.2018.2(part1).129510

The level of proteinuria and the state of endothelial function in patients with chronic kidney disease combined with subclinical hypothyroidism under the influence of combined antihypertensive therapy.

O. V. Kuryata, I. P. Garmish

Abstract


Our aim was to assess the level of proteinuria and changes in vascular endothelial function in patients with chronic kidney disease (CKD) in combination with subclinical hypothyroidism (SHT) under the influence of antihypertensive combination therapy (valsartan 160 mg and amlodipine 5 mg). We examined 48 patients with CKD I-II stages and AH 1 and 2 degrees. Depending on the functional state of the thyroid gland, patients were divided into 2 groups. Within 12 weeks patients took a fixed combination of amlodipine 5 mg and valsartan 160 mg. Target BP levels were achieved in 19 (86.3%) patients of the main group and 22 (84.6%) of the comparison group. More often violation of brachial artery flow-mediated dilation and higher level of daily proteinuria were found in the main group patients. At the end of the study, the level of daily proteinuria in the main group decreased by 46.03% (p<0.01), and in the comparison group – by 55.3% (p<0.01). SHT can be considered as an additional factor that affects the course of CKD and AH by worsening the state of endothelial function and increasing the level of daily proteinuria. Combination of valsartan 160 mg and amlodipine 5 mg has lead to achieving of target blood pressure levels, improving of endothelial function and decreasing of daily proteinuria in both groups.

 


Keywords


chronic kidney disease; arterial hypertension; subclinical hypothyroidism; combined antihypertensive therapy

References


Kuryata OV, Karapetjan KG, Bardachenko NI, Garmish IP. [Possibilities of correction of cognitive func­tions and anxiety-depressive disorders in the complex therapy of arterial hypertension, depending on the func­tional state of the kidneys]. Journal of neuroscience of BM Mankovskyi. 2015;3(3):5-10. Russian.

Zaremba Je, Zaremba-Fedchyshyn O, Virna M. [Op­timization of combined antihypertensive therapy in patients with arterial hypertension, depending on the indicators of daily blood pressure monitoring]. Semejnaja medycyna. 2017;2 (70):67-71. Ukrainian.

Kuryata OV, Garmish IP. [The effectiveness of combined antihypertensive therapy in patients with chro­nic kidney disease combined with subclinical hypo­thyroidism]. Semeynaya meditsina. 2017;3(71):22-27. Ukrainian.

Кushnir JS. [Hemodynamics, functional state of the endothelium, kidneys and platelets depending on the body mass index in patients with chronic heart failure with preserved systolic function]. Medicni perspektivi. 2014;ХІХ(1):29-36. Ukrainian.

Lapshin OV. [Combined antihypertensive therapy - a modern trend of treatment]. Liky Ukrainy. 2013;1(167):30-37. Ukrainian.

Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of theAmericanCollegeof Cardiology. American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017;13.

Cooper D, Biondi B. Subclinical thyroid disease. Lancet. 2012;379(9821):1142-54.

Leung AA, Daskalopoulou SS, Dasgupta K, et al. Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hyper­tension in Adults. Canadian Journal of cardiology. 2017;33(5):557-76.

Chongol M, Lippi G, Salvagno G, Zoppini G, Michele M, Giovanni T. Prevalence of Subclinical hypo­thyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(5):1296-300.


GOST Style Citations


  1. Возможности коррекции когнитивных функ­ций и тревожно-депрессивных расстройств в комплексной терапии артериальной гипертензии в зависимости от функционального состояния почек / А.В. Курята, К.Г. Карапетян, Н.И. Бардаченко, И.П. Гармиш // J. Neuroscience B.M. Mankovskyi. – 2015. – № 3 (3). – С. 5-10.
  2. Заремба Є. Оптимізація комбінованої анти­гіпертензивної терапії у хворих на артеріальну гіпер­тензію залежно від показників добового моніторингу артеріального тиску / Є. Заремба, О. Заремба-Фед­чишин, М. Вірна // Сімейна медицина. — 2017. — № 2 (70). — C.67-71.
  3. Курята О.В. Ефективність комбінованої анти­гіпертензивної терапії у пацієнтів з хронічною хво­робою нирок у поєднанні з субклінічним гіпоти­реозом / О.В. Курята, І. П. Гарміш // Семейная меди­цина. – 2017. - №3 (71). – с.22-27.
  4. Кушнір Ю.С. Гемодинаміка, функціональний стан ендотелію судин, нирок та тромбоцитів залежно від індексу маси тіла при хронічній серцевій не­достатності зі збереженою систолічною функцією / Ю.С. Кушнір // Медичні перспективи. – 2014. – Т. ХІХ, № 1. – С. 29-36.
  5. Лапшин О.В. Комбінована антигіпертензивна терапія – сучасний тренд лікування / О. Лапшин // Ліки України. — 2013. — № 1 (167). — C.30-37.
  6. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of theAmericanCollegeof Cardiology. American Heart Association Task Force on Cli­nical Practice Guidelines / P.K. Whelton, R.M. Carey, W.S. Aronow [et al.] // J. Am. Coll. Cardiol. – 2017. – N 13.
  7. Cooper D. Subclinical thyroid disease / D. Coo­per, B.  Biondi // Lancet.- 2012.- Vol. 379, N 9821.- P. 1142-1154.
  8. Hypertension Canada's 2017 Guidelines for Diag­nosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults / A.A. Leung, S.S. Daskalo­pou­lou, K. Dasgupta [et al.] // Canad. J. Cardiology. – 2017. – Vol. 33, N 5. – P. 557-576.
  9. Prevalence of Subclinical hypothyroidism in pa­tients with chronic kidney disease / M. Chongol, G. Lippi, G.Salvagno, G. Zoppini // Clin. J. Am. Soc. Nephrol. – 2008. – Vol. 3, N 5. – P. 1296-1300.